


LISTING OF CLAIMS

This listing of claims replaces all prior versions.

1. (Currently amended) A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused-aromatic ring benzene;

R_C is -CH₂-R_L;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

- 2-3. (Cancelled)

4. (Currently amended) A method according to claim 3 1, wherein the fused ~~aromatic ring~~ benzene is unsubstituted.

5. to 9. (Cancelled).


10. (Previously presented) A method according to claim 1, wherein R_L is substituted by one or more substituents selected from the group consisting of: C₁₋₇ alkyl; C₅₋₂₀ aryl;

C₃₋₂₀ heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; acylamido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

11. (Currently amended) A method according to claim 10, wherein R_L is substituted by a substituent selected from the group consisting of: an acylamido, ureido, sulfonamino, and wherein the acylamido is ureido, acyloxy or an amino, wherein the amino is sulfonamido.

12. (Original) A method according to claim 1, wherein the disease mediated by PARP is cancer, and there is additionally administered to the subject chemotherapy or radiation therapy.

13. (Currently amended) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:


A and B together represent ~~an~~ optionally substituted, fused ~~aromatic ring~~ benzene;

R_C is -CH₂-R_L;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

14. (Currently amended) A compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally monosubstituted, fused-aromatic ring benzene;

R_C is -CH₂-R_L;

R_L is ~~optionally~~ substituted phenyl, wherein the substituents are selected from the group consisting of: C₅₋₂₀ aryl; C₃₋₂₀ heterocyclyl; ester; amido; acyloxy; sulfonamido; cyano; ureido; acylamido; thioether; thiol; SO₂R wherein R is C₁₋₇ alkyl, C₃₋₂₀ heterocyclyl or C₅₋₂₀ aryl; and sulfoxide, and optionally further substituted; and

R_N is hydrogen.


15-16. (Cancelled)

17. (Currently amended) A compound according to claim ~~16~~ 14, wherein the fused ~~aromatic ring benzene~~ is unsubstituted.

18. (Cancelled)

19. (Currently amended) A compound according to claim ~~18~~ 14, wherein R_L is substituted by ~~a substituent selected from the group consisting of: an acylamido, ureido, sulfonamino, and~~ wherein the acylamido is ureido, acyloxy or a sulfonamido.

20. (Currently amended) A pharmaceutical composition comprising a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused ~~aromatic ring~~ benzene;

R_C is -CH₂-R_L;

R_L is optionally substituted phenyl; and

R_N is hydrogen;

and a pharmaceutically acceptable carrier or diluent.

21-22. (Cancelled)


23. (Currently amended) The pharmaceutical composition of claim ~~22~~ 20, wherein the fused ~~aromatic ring~~ benzene is unsubstituted.

24. (Previously presented) The pharmaceutical composition of claim 20, wherein R_L is substituted by one or more substituents selected from the group consisting of: C₁₋₇ alkyl; C₅₋₂₀ aryl; C₃₋₂₀ heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; acylamido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

25. (Currently amended) The pharmaceutical composition of claim 24, wherein R_L is substituted by ~~a substituent selected from the group consisting of: an acylamido, ureido,~~


~~sulfonamino, and wherein the acylamido is ureido, acyloxy or an amino, wherein the amino is sulfonamido.~~

26. (Previously presented) A method of treatment of a disease of a human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of the formula:




or an isomer, salt, solvate, chemically protected form and prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

27. (Previously presented) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof.

28. (Previously presented) A compound of the formula:



or an isomer, salt, solvate, chemically protected form and prodrug thereof.